Bausch + Lomb announced the FDA approved the enVista Envy full range of vision IOL, which offers a continuous range of vision with excellent dysphotopsia tolerance on the enVista IOL platform, the company said in a press release.
According to Bausch + Lomb, Envy delivers outstanding performance in all lighting conditions due to ActivSync Optic intelligent energy distribution, which optimizes vision in many lighting conditions. In addition, the company says, Envy also enables surgeons to treat a wider range of astigmatic patients with more accuracy and precision with 0.5 D steps (or less) throughout the cylinder range.
enVista Envy IOLs will be commercially available in the United States on a limited basis in the coming weeks and more broadly in 2025. Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets, the company said.
According to Bausch + Lomb, a multicenter, randomized and controlled clinical trial evaluating 332 subjects demonstrated excellent long-term outcomes with the enVista Envy IOL in the United States.1 On average, 86% of patients reported little to no bothersomeness for dysphotopsia (glare, halo, starbursts), showing an impressive tolerance profile overall.1 In a Canadian clinical study evaluating 110 subjects, 94% of patients reported little to no difficulty viewing close objects, and 93% were completely to moderately satisfied with their vision post-surgery.2
References
- Data on file. enVista Envy U.S. Clinical Study.
- Data on file. enVista Envy Canadian Clinical Study.